Brokerages Set Endo International plc (NASDAQ:ENDP) PT at $8.19

Endo International plc (NASDAQ:ENDP) (TSE:ENL) has received an average recommendation of “Hold” from the eleven analysts that are presently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $8.19.

Several research firms have weighed in on ENDP. Citigroup lifted their target price on Endo International from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, May 17th. Morgan Stanley lifted their target price on Endo International from $5.00 to $7.00 and gave the stock an “underweight” rating in a report on Wednesday, March 3rd. Royal Bank of Canada began coverage on Endo International in a report on Wednesday, April 7th. They set a “sector perform” rating and a $7.00 target price on the stock. Barclays lifted their target price on Endo International from $6.00 to $7.00 and gave the stock an “equal weight” rating in a report on Monday, March 8th. Finally, TheStreet lowered Endo International from a “c” rating to a “d+” rating in a report on Thursday, May 6th.

NASDAQ:ENDP opened at $6.05 on Tuesday. Endo International has a 12-month low of $2.71 and a 12-month high of $10.89. The company has a market cap of $1.41 billion, a price-to-earnings ratio of 15.13 and a beta of 1.45. The business has a fifty day moving average of $5.89.

Endo International (NASDAQ:ENDP) (TSE:ENL) last posted its quarterly earnings results on Thursday, May 6th. The company reported $0.73 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.48 by $0.25. Endo International had a negative return on equity of 91.08% and a net margin of 3.41%. The business had revenue of $718.00 million for the quarter, compared to analyst estimates of $666.90 million. During the same period last year, the company earned $0.95 EPS. The firm’s revenue was down 12.4% on a year-over-year basis. Equities analysts predict that Endo International will post 2.16 EPS for the current year.

In related news, Director Shane Cooke sold 17,290 shares of Endo International stock in a transaction dated Monday, March 15th. The stock was sold at an average price of $8.65, for a total value of $149,558.50. Following the sale, the director now owns 97,104 shares of the company’s stock, valued at $839,949.60. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.70% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Captrust Financial Advisors increased its position in Endo International by 568.6% during the first quarter. Captrust Financial Advisors now owns 5,128 shares of the company’s stock worth $38,000 after buying an additional 4,361 shares during the last quarter. Carolina Wealth Advisors LLC increased its position in Endo International by 109.5% during the first quarter. Carolina Wealth Advisors LLC now owns 8,894 shares of the company’s stock worth $66,000 after buying an additional 4,648 shares during the last quarter. One Wealth Advisors LLC acquired a new position in Endo International during the first quarter worth approximately $88,000. Vantage Consulting Group Inc acquired a new position in Endo International during the fourth quarter worth approximately $89,000. Finally, Nisa Investment Advisors LLC increased its position in Endo International by 131.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 17,700 shares of the company’s stock worth $127,000 after buying an additional 10,050 shares during the last quarter. 80.86% of the stock is currently owned by hedge funds and other institutional investors.

About Endo International

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology.

Recommended Story: After-Hours Trading

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.